Galunisertib and M7824, molecules targeted to block the TGFβ signaling pathway, have already been used in the clinical treatment of a variety of cancers (30–32); they may now become a new treatment for AGC rather than for all GC patients. The gene discussed is TGFB1; the disease is gastric cancer.